Leveraging Epigenetics to Enhance the Cellular Response to Chemotherapies and Improve Tumor Immunogenicity

Tyutyunyk‐Massey, Liliya; Haqqani, Syed; Mandava, Reshma; Kentiba, Kirubel; Dammalapati, Mallika; Dao, Nga; Haueis, Joshua; Gewirtz, David A.; Landry, Joseph W.

doi:10.1016/bs.acr.2018.02.001

Cited by 1 publication

(2 citation statements)

References 193 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In an analogy to the driver and passenger mutations mentioned above, concepts have now emerged for "driver epigenetic" events that may influence the metastatic potential. Such 'epi-driver' and 'epipassenger' events in metastasis may provide for better understanding of the biological processes and also provide for new areas for therapeutic targets [56,57,60]. Taken together, the epigenome cooperates with the genome as cancers develop and eventually metastasize [56,57] with the potential for exploring novel biomarkers of risk or monitoring of disease and, drugable targets for therapy.…”

Section: Epigenetics In Cancer Evolutionmentioning

confidence: 99%

See 1 more Smart Citation

Cancer epigenetics in solid organ tumours: A primer for surgical oncologists

Drake

Søreide

2019

European Journal of Surgical Oncology

View full text Add to dashboard Cite

Cancer is initiated through both genetic and epigenetic alterations. The end-effect of such changes to the DNA machinery is a set of uncontrolled mechanisms of cell division, invasion and, eventually, metastasis. Epigenetic changes are now increasingly appreciated as an essential driver to the cancer phenotype. The epigenetic regulation of cancer is complex and not yet fully understood, but application of epigenetics to clinical practice and in cancer research has the potential to improve cancer care. Epigenetics changes do not cause changes in the DNA base-pairs (and, hence, does not alter the genetic code per se) but rather occur through methylation of DNA, by histone modifications, and, through changes to chromatin structure to alter genetic expression. Epigenetic regulators are characterized as writers, readers or erasers by their mechanisms of action. The human epigenome is influenced from cradle to grave, with internal and external life-time exposure influencing the epigenetic marks that may act as modifiers or drivers of carcinogenesis. Preventive and public health strategies may follow from better understanding of the lifetime influence of the epigenome. Epigenetics may be used to define risk, to investigate mechanisms of carcinogenesis, to identify biomarkers, and to identify novel therapeutic options. Epigenetic alterations are found across many solid cancers and are increasingly making clinical impact to cancer management. Novel epigenetic drugs may be used for a more tailored and specific response to treatment of cancers. We present a primer on epigenetics for surgical oncologists with examples from colorectal cancer, breast cancer, pancreatic cancer and hepatocellular carcinoma.

show abstract

Section: Epigenetics In Cancer Evolutionmentioning

confidence: 99%

“…for measure of response or as indicator of recurrence. Finally, specific epigenetic drugs may be used together with conventional drugs to achieve a more tailored and specific response to the specific cancer under treatment [20,57,60,64,65].…”

Section: Potential Clinical Implications Of Epigeneticsmentioning

confidence: 99%

Cancer epigenetics in solid organ tumours: A primer for surgical oncologists

Drake

Søreide

2019

European Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

Leveraging Epigenetics to Enhance the Cellular Response to Chemotherapies and Improve Tumor Immunogenicity

Cited by 1 publication

References 193 publications

Cancer epigenetics in solid organ tumours: A primer for surgical oncologists

Cancer epigenetics in solid organ tumours: A primer for surgical oncologists

Contact Info

Product

Resources

About